Dr. Kris on How the Institutes in His Study Worked Together

Mark G. Kris, MD
Published: Thursday, Jul 28, 2011



Lead author Mark G. Kris, MD, chief of the Thoracic Oncology Service at Memorial Sloan-Kettering Cancer Center, describes the multicenter study that focused on the identification of driver mutations from tumor specimens in patients with lung adenocarcinoma. He explains that the institutes involved in the study shared information with each but did not share tissue samples.

Kris points out the trial was unique because it did not conduct exploratory research or look at prognostics, but instead focused on improving treatment through identification of mutations. The trial focused on identifying KRAS, EGFR, HER2, BRAF, PIK3CA, AKT1, MEK1, and NRAS mutations using standard multiplexed assays and FISH for EML4-ALK rearrangements and MET amplifications.


Lead author Mark G. Kris, MD, chief of the Thoracic Oncology Service at Memorial Sloan-Kettering Cancer Center, describes the multicenter study that focused on the identification of driver mutations from tumor specimens in patients with lung adenocarcinoma. He explains that the institutes involved in the study shared information with each but did not share tissue samples.

Kris points out the trial was unique because it did not conduct exploratory research or look at prognostics, but instead focused on improving treatment through identification of mutations. The trial focused on identifying KRAS, EGFR, HER2, BRAF, PIK3CA, AKT1, MEK1, and NRAS mutations using standard multiplexed assays and FISH for EML4-ALK rearrangements and MET amplifications.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Updates in Novel Therapeutic Options for Lung Neuroendocrine TumorsMay 31, 20181.0
Community Practice Connections™: Working Group to Optimize Outcomes in EGFR-mutated Lung Cancers: Evolving Concepts for Nurses to Facilitate and Improve Patient CareJun 30, 20181.5
Publication Bottom Border
Border Publication
x